Desensitization protocols improving access and outcome in transplantation

Andrea A. Zachary, Robert A. Mongomery, Mary S. Leffell

Research output: Contribution to journalArticle

Abstract

Sensitization to antigens of the HLA and ABO system has been the biggest barrier to access in renal transplantation and, increasingly, in transplantation of other organs. Additionally, antibody to donor antigens has been shown to result in injury to the graft ranging from catastrophic, irreversible hyperacute rejection to the slower, more insidious, chronic form of rejection. The problem of access has been recognized globally and has been the incentive for measures to overcome the disadvantage experienced by the sensitized patient. However, early attempts to reduce sensitization achieved only transient success. Newer immunosuppressive agents that affect B-cell function or viability have permitted the development of treatment protocols to eliminate and, potentially, downregulate donor-specific antibodies. The use of these protocols has achieved successful transplants that were HLA and/or ABO incompatible prior to treatment and, as such, has provided some patients with their only opportunity for transplantation.

Original languageEnglish (US)
Pages (from-to)373-395
Number of pages23
JournalClinical and Applied Immunology Reviews
Volume5
Issue number6
DOIs
StatePublished - Nov 2005

Fingerprint

Transplantation
Transplants
Antibodies
Organ Transplantation
Immunosuppressive Agents
Clinical Protocols
HLA Antigens
Kidney Transplantation
Motivation
B-Lymphocytes
Down-Regulation
Tissue Donors
Antigens
Wounds and Injuries
Rejection (Psychology)
Psychologic Desensitization
Therapeutics

Keywords

  • ABO incompatible transplantation
  • Desensitization
  • Double filtration plasmapheresis
  • HLA-specific antibody
  • Intravenous immunoglobulin (IVIg)
  • Plasmapheresis
  • Sensitization
  • Transplantation

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Desensitization protocols improving access and outcome in transplantation. / Zachary, Andrea A.; Mongomery, Robert A.; Leffell, Mary S.

In: Clinical and Applied Immunology Reviews, Vol. 5, No. 6, 11.2005, p. 373-395.

Research output: Contribution to journalArticle

Zachary, Andrea A. ; Mongomery, Robert A. ; Leffell, Mary S. / Desensitization protocols improving access and outcome in transplantation. In: Clinical and Applied Immunology Reviews. 2005 ; Vol. 5, No. 6. pp. 373-395.
@article{24e2fb5ba6464ce58ac3d66e0ecb1e8d,
title = "Desensitization protocols improving access and outcome in transplantation",
abstract = "Sensitization to antigens of the HLA and ABO system has been the biggest barrier to access in renal transplantation and, increasingly, in transplantation of other organs. Additionally, antibody to donor antigens has been shown to result in injury to the graft ranging from catastrophic, irreversible hyperacute rejection to the slower, more insidious, chronic form of rejection. The problem of access has been recognized globally and has been the incentive for measures to overcome the disadvantage experienced by the sensitized patient. However, early attempts to reduce sensitization achieved only transient success. Newer immunosuppressive agents that affect B-cell function or viability have permitted the development of treatment protocols to eliminate and, potentially, downregulate donor-specific antibodies. The use of these protocols has achieved successful transplants that were HLA and/or ABO incompatible prior to treatment and, as such, has provided some patients with their only opportunity for transplantation.",
keywords = "ABO incompatible transplantation, Desensitization, Double filtration plasmapheresis, HLA-specific antibody, Intravenous immunoglobulin (IVIg), Plasmapheresis, Sensitization, Transplantation",
author = "Zachary, {Andrea A.} and Mongomery, {Robert A.} and Leffell, {Mary S.}",
year = "2005",
month = "11",
doi = "10.1016/j.cair.2005.10.002",
language = "English (US)",
volume = "5",
pages = "373--395",
journal = "Clinical and Applied Immunology Reviews",
issn = "1529-1049",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Desensitization protocols improving access and outcome in transplantation

AU - Zachary, Andrea A.

AU - Mongomery, Robert A.

AU - Leffell, Mary S.

PY - 2005/11

Y1 - 2005/11

N2 - Sensitization to antigens of the HLA and ABO system has been the biggest barrier to access in renal transplantation and, increasingly, in transplantation of other organs. Additionally, antibody to donor antigens has been shown to result in injury to the graft ranging from catastrophic, irreversible hyperacute rejection to the slower, more insidious, chronic form of rejection. The problem of access has been recognized globally and has been the incentive for measures to overcome the disadvantage experienced by the sensitized patient. However, early attempts to reduce sensitization achieved only transient success. Newer immunosuppressive agents that affect B-cell function or viability have permitted the development of treatment protocols to eliminate and, potentially, downregulate donor-specific antibodies. The use of these protocols has achieved successful transplants that were HLA and/or ABO incompatible prior to treatment and, as such, has provided some patients with their only opportunity for transplantation.

AB - Sensitization to antigens of the HLA and ABO system has been the biggest barrier to access in renal transplantation and, increasingly, in transplantation of other organs. Additionally, antibody to donor antigens has been shown to result in injury to the graft ranging from catastrophic, irreversible hyperacute rejection to the slower, more insidious, chronic form of rejection. The problem of access has been recognized globally and has been the incentive for measures to overcome the disadvantage experienced by the sensitized patient. However, early attempts to reduce sensitization achieved only transient success. Newer immunosuppressive agents that affect B-cell function or viability have permitted the development of treatment protocols to eliminate and, potentially, downregulate donor-specific antibodies. The use of these protocols has achieved successful transplants that were HLA and/or ABO incompatible prior to treatment and, as such, has provided some patients with their only opportunity for transplantation.

KW - ABO incompatible transplantation

KW - Desensitization

KW - Double filtration plasmapheresis

KW - HLA-specific antibody

KW - Intravenous immunoglobulin (IVIg)

KW - Plasmapheresis

KW - Sensitization

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=32544450007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32544450007&partnerID=8YFLogxK

U2 - 10.1016/j.cair.2005.10.002

DO - 10.1016/j.cair.2005.10.002

M3 - Article

AN - SCOPUS:32544450007

VL - 5

SP - 373

EP - 395

JO - Clinical and Applied Immunology Reviews

JF - Clinical and Applied Immunology Reviews

SN - 1529-1049

IS - 6

ER -